Platelet-rich plasma injection versus surgical and medical treatment of mild-moderate carpal tunnel syndrome

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

article

Eltabl, MA¹  Saif, DS¹  Alemam, SE¹ 

[1] Faculty of medicine, Menoufia University

关键词: PRP;    Carpal tunnel syndrome;    Nerve conduction study;    VAS;    Injection medical treatment;   

DOI  :  10.1186/s41983-020-00186-z

学科分类：医学（综合）

来源: Springer

【 摘 要 】

Carpal tunnel syndrome (CTS) accounts for approximately 90% of peripheral entrapment neuropathy cases. Treatments of CTS as splinting, corticosteroid injection, and surgery are not 100% effective, and alternative treatments are worth exploring. Surgery indicated in patients with persistent numbness, pain, and motor dysfunction. Empirical evidence indicates that many patients with CTS respond to anti-inflammatory medications. Recently, major attention has been drawn to platelet-rich plasma (PRP) for its possible effects on axon regeneration and neurological recovery. To evaluate the therapeutic efficacy of single ultrasound guided PRP injection of CTS versus surgical procedures and medical treatment in patients with mild-moderate CTS regarding pain relief and function improvement. Thirty patients were injected in the carpal tunnel with single ultrasound-guided PRP (1–2 ml) injections; 30 patients went to surgical procedure, and 30 patients received conventional medical treatment and hand support. They were followed by using VAS (visual analogue scale), Boston questionnaire for CTS, and nerve conduction study for clinical improvement. Both groups of patients who had received PRP injection and who underwent to surgery showed improvements in their scores of evaluation parameters at 6 months post intervention, while the third group that received medical treatment shows insignificant improvement at 6 months post treatment. PRP can be considered as a safe, less invasive, and long-lasting alternative to surgery and effective with one shot session compared to medical treatment in management of mild-moderate CTS. Clinical trial.govID: NCT04235426 . Unique protocol ID:1472. Verification date: January 2020.

【 授权许可】

CC BY